Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for Intellia Therapeutics (NTLA) over the last 9 years, with Dec 2024 value amounting to $26.4 million.

  • Intellia Therapeutics' Other Accumulated Expenses fell 35.40% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 35.40%. This contributed to the annual value of $26.4 million for FY2024, which is 3.83% down from last year.
  • As of FY2024, Intellia Therapeutics' Other Accumulated Expenses stood at $26.4 million, which was down 3.83% from $27.4 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Other Accumulated Expenses registered a high of $32.7 million during FY2022, and its lowest value of $11.0 million during FY2020.
  • For the 3-year period, Intellia Therapeutics' Other Accumulated Expenses averaged around $28.8 million, with its median value being $27.4 million (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Other Accumulated Expenses skyrocketed by 161.60% in 2020, and later decreased by 16.13% in 2023.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Other Accumulated Expenses stood at $11.0 million in 2020, then spiked by 54.24% to $17.0 million in 2021, then spiked by 92.50% to $32.7 million in 2022, then dropped by 16.13% to $27.4 million in 2023, then dropped by 3.83% to $26.4 million in 2024.